Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phenylephrine, Long Time On Market For Hypotension, Goes To FDA Panel

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency seeks counsel on whether elevation in blood pressure is sufficient clinical benefit to approve the literature-based NDA for West-Ward Pharmaceutical’s product, which is currently an unapproved drug.

You may also be interested in...

Endpoint Selection Still An Issue For Publication-Based NDAs

FDA’s Cardiovascular and Renal Drugs Advisory Committee Sept. 13 indicated approval for currently marketed phenylephrine to treat hypotension in the peri-operative setting based on the ability to increase blood pressure, but voted 8-2 against its use in shock because of the need for outcomes data.

Sept. 19, 2011: The Day FDA’s Discretion On Unapproved Drugs Stood Still

FDA is drawing a line in the sand when it comes to unapproved drugs, and that line begins at Sept. 19, 2011.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts